Potential cost-effectiveness and benefit-cost ratios of adult pneumococcal vaccination in Germany

Alexander Kuhlmann (), Ulrike Theidel (), Mathias Pletz () and Johann Graf von der Schulenburg

Health Economics Review, 2012, vol. 2, issue 1, 1-13

Abstract: Results of the model indicate that the health economic benefit of immunizing adults with PCV13 can be expected to outperform the sole use of PPV23, if the effectiveness of PCV13 is comparable to the effectiveness of PCV7. Copyright Kuhlmann et al.; licensee Springer. 2012

Keywords: Cost; Effectiveness; Pneumococcal polysaccharide vaccine; Pneumococcal conjugate vaccine; Adult; Benefit-cost (search for similar items in EconPapers)
Date: 2012
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (4)

Downloads: (external link)
http://hdl.handle.net/10.1186/2191-1991-2-4 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:hecrev:v:2:y:2012:i:1:p:1-13:10.1186/2191-1991-2-4

Ordering information: This journal article can be ordered from
http://www.springer.com/journal/13561

DOI: 10.1186/2191-1991-2-4

Access Statistics for this article

Health Economics Review is currently edited by J. Matthias Graf von der Schulenburg

More articles in Health Economics Review from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().